News – Page 945 – Endpoints News

SIGN UP

Protocols: Did Ionis set out to exclude side effects? Merck takes another step forward with Lantus biosimilar

8 years ago

Woodford gets slammed with a brutal set of portfolio hits, as Northwest continues to fester

8 years ago

Thumbs Up/Thumbs Down: The new buzz in R&D, blockbuster work on a budget and why what’s dead may never die

8 years ago

Bristol-Myers craters after blockbuster checkpoint drug Opdivo fails key lung cancer study

8 years ago

Gemphire IPO staggers into the market, reaping $30M

8 years ago

Deaths derail Juno's launch countdown, giving Kite and Novartis the lead

8 years ago

Pushed by high costs in Cambridge, fast-growing Decibel makes a pioneering leap to Fenway

8 years ago

Momenta hit with a setback as pancreatic cancer drug flops in PhII

8 years ago

Regeneron makes a blockbuster case for its PhIII drug pipeline

8 years ago

BioRegnum: What’s the deal with Biogen?

8 years ago

Adaptimmune gets a partial hold on pivotal T-cell study, but it seems OK to breathe now

8 years ago

Protocols: Editas adds CRISPR/Cas9 IP; biosimilars make fresh gains in U.S. market

8 years ago

Takeda rests its R&D footprint on U.S. hubs

8 years ago

As doubts continue to fester, Inovio gets another shove as Roche exits collaboration

8 years ago

Novartis’ star cancer drug lands on an inside FDA track, racing Lilly to a showdown with Pfizer

8 years ago

Baxalta in hand, Shire dumps drug programs in hunt for $210M in R&D cuts

8 years ago

A few key reasons why Biogen has now become a buzzed about takeover target

8 years ago

Protocols: Troubled Telesta axes staff in wake of FDA rejection; Evelo partners with Mayo researchers

8 years ago

Biotech vet MacKay grabs a $25M A round to back a gene therapy upstart

8 years ago

BioRegnum: The miracle drug story that just won’t die

8 years ago

Amgen barrels into a $540M immunotherapy deal with Advaxis

8 years ago

Regeneron leaps into the blockbuster race to develop off-the-shelf immune cell cancer therapies

8 years ago

Pfizer boosts its gene therapy work, bags upstart Bamboo in $645M buyout deal

8 years ago

Protocols: Private equity buy-in values inVentiv at $3.8B; Celgene denies charity scheme allegations

8 years ago

First page Previous page 942 943 944945946 947 948 Next page Last page